|
Author
|
Dose scheme
|
No. of patients
|
Median follow-up (moths)
|
FFBF (in % by risk group)
|
Early toxicity in %
|
Late toxicity in %
|
Patients receiving ADT in %
|
|---|
|
low (l)
|
intermediate (i)
|
high (h)
|
GU
|
GI
|
GU
|
GI
|
|---|
|
G1
|
G2
|
G3
|
G1
|
G2
|
G3
|
G3
|
G3
| |
|---|
|
Friedland et al. 2009[5]
|
7 and 7.25 Gy × 5
|
112
|
24
| |
l,i,h: 97.3
| | | | | | | |
0
|
1
|
19
|
|
Bolzicco et al. 2010[17]
|
7 Gy × 5
|
45
|
20
|
l,i:100
| |
36
|
11
|
0
|
24
|
24
|
0
|
22
|
0
|
38
|
|
Freeman et al. 2011[18]
|
7 and 7.25 Gy × 5
|
41
|
60
|
92.7
| | | | | |
*
| | |
25
|
0
|
0
|
|
Kang et al. 2011[19]
|
8,8.5, and 9 Gy × 4
|
44
|
40
|
100
|
100
|
90.8
|
n.A.
|
14
|
0
|
n.A.
|
9
|
0
|
0
|
0
|
87
|
|
King et al. 2012[20]
|
7.25 Gy × 5
|
67
|
32
|
94 (4-year)
| | | | | | | | |
3
|
0
|
0
|
|
McBride et al. 2012[21]
|
7.25 and 7.25 Gy × 5
|
45
|
44
|
97.7 (3-year)
| | |
59
|
19
|
0
|
31
|
7
|
0
|
2
|
5
|
0
|
|
Oliai et al. 2012[2]
|
7,7.25 and 7.5 Gy × 5
|
70
|
31
|
100
|
94.7
|
77.1
|
56
|
19
|
4
|
17
|
4
|
0
|
3
|
0
|
33
|
|
Katz et al. 2013[4]
|
7 and 7.25 Gy × 5
|
304
|
60
|
97.7 (3-year)
|
90.7
|
74.1
|
72-75
|
4-5
|
0
|
75-76
|
4
|
0
|
2
|
0
|
19
|
|
Chen et al. 2013[3]
|
7 and 7.25 Gy × 5
|
100
|
28
|
100
|
100
|
88
|
36
|
35
|
0
|
35
|
5
|
0
|
0
|
<1
|
11
|
|
King 2013[6], pooled date
|
7-7.25 Gy × 5
|
1100
|
36
|
95
|
83
|
78
| | | | | | | | |
14
|
- *Acute symptoms typically resolved within one month of treatment completation.
- FFBF: freedom from biochemical failure, GU: genitourinary, GI: gastrointestinal, G: Grade, ADT: androgen deprivation therapy.
